FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology. Methods of genotyping and compositions for selecting patients suffering cardiovascular disease, which can be benefited by therapy raising HDL level or imitating HDL agent, in particular inhibitor/modulator of esterificated cholesterol carrier protein (CETP).
EFFECT: invention discloses genetic markers for predicting a response to therapy by raising the level of HDL or imitating HDL agents.
96 cl, 10 dwg, 13 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GENETIC MARKERS FOR PREDICTION OF SUSCEPTIBILITY TO THERAPY | 2014 |
|
RU2707533C2 |
| GENETIC MARKERS FOR PREDICTING SENSITIVITY TO THERAPY | 2014 |
|
RU2809215C2 |
| BIOMARKERS FOR ESTIMATING EFFICACY OF ALISKIREN AS HYPERTENSIVE AGENT | 2006 |
|
RU2408363C2 |
| PREDICTION OF PROGRESSION OF AGE-RELATED MACULAR DYSTROPHY TO LATE STAGE BY MEANS OF POLYGENE INDICATOR | 2011 |
|
RU2593954C2 |
| DIAGNOSTIC TECHNIQUE FOR GENETIC PREDISPOSITION TO CARDIAC CONDUCTION DISORDER | 2013 |
|
RU2528900C1 |
| VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY | 2008 |
|
RU2482491C2 |
| VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY | 2013 |
|
RU2635525C2 |
| METHOD OF FINDING PRONENESS TO HIGH-ALTITUDE PULMONARY EDEMA | 2003 |
|
RU2353656C2 |
| PREDICTION OF KINETICS OF HEPATITIS C VIRUS IN INTERFERON-EXCLUDING TREATMENT | 2011 |
|
RU2590691C2 |
| METHOD FOR PREDICTING THE DVELOPMENT FOR HYPERTONIC DISEASE ACCORDING TO GENETIC RISK FACTORS | 2005 |
|
RU2287158C1 |
